FTSE MIB
34.660,38 -173,92 (-0,50%) Dow Jones
38.798,99 -87,18 (-0,22%) Nasdaq
17.133,12 -40,00 (-0,23%) Nikkei 225
38.683,93 -19,58 (-0,05%) Petrolio
75,38 -0,17 (-0,23%) Bitcoin EUR
64.173,69 +16,35 (+0,03%)
CLLS Aug 2024 2.500 put
| Chiusura precedente | 0,4000 |
| Aperto | 0,4000 |
| Denaro | 0,1000 |
| Domanda | 0,4000 |
| Prezzo d'esercizio | 2,50 |
| Scadenza | 2024-08-16 |
| Min-Max giorno | 0,4000 - 0,4000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 138 |
GlobeNewswireCellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy – Methods & Clinical Development, demonstrating the efficacy of its TALEN-mediated gene correction of mutated PIK3CD gene in APDS1 T-cells. The research work described in this articl
- GlobeNewswire
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority)PARIS, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights09/30/202355,583,76861,519,946 About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherap
- GlobeNewswire
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on MUC1-CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023), that will take place on November 1-5, 2023 at San
